Vascular Invasion in Renal Cell Carcinoma
Research type
Research Study
Full title
Direct Oral Anticoagulants: Study of their effect on Vascular Invasion in Renal Cell Carcinoma (the DORC study)
IRAS ID
223240
Contact name
Anthony Maraveyas
Contact email
Sponsor organisation
University of Hull
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
The study will investigate whether direct oral anticoagulant (DOAC) drugs, which inhibit activated clotting factors, can have anti-inflammatory effects on endothelial cells by inhibiting activation of protease-activated receptors (PAR-1 and PAR-2). This is turn could prevent endothelial cell apoptosis and vascular damage, which can contribute to the formation of blood clots. Microvesicles isolated from blood samples of patients with kidney cancer (or renal cell carcinoma, RCC) will be applied to endothelial cells in the presence of DOACs and the effect on the induction of apoptosis will be measured.
A second component of the study will focus on the ability of RCC to invade the venous system, resulting in an extension of the tumour called a ‘tumour thrombus’. Diagnostic biopsy samples from RCC patients will be examine for potential changes in levels of markers of endothelial cell damage and/or activation that might explain a role for this tumour thrombus in causing local inflammation.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
18/YH/0008
Date of REC Opinion
31 Jan 2018
REC opinion
Favourable Opinion